We are excited to announce the Dynavax DV3-MEL-01 study for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) is now open to recruitment.  Head and Neck cancer includes cancer of the tongue, gum, mouth, salivary glands, tonsils, pharynx, nasal cavity and larynx.  This study is testing a new therapy in combination with Keytruda (pembrolizumab) immunotherapy.  More information about the study can be found here.

If you would to discuss this study, you can speak to our oncology nurses on (08) 9446 8726 or email us info@affinityresearch.com.au .

#clinicaltrials #headandneckcancer #hnscc


Affinity Clinical Research Services Newsletter

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.


You have Successfully Subscribed!